{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:18:37Z","timestamp":1790518717059,"version":"4.1.0"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:00:00Z","timestamp":1570060800000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"British Medical Research Programme","award":["MR\/S00081X\/1"],"award-info":[{"award-number":["MR\/S00081X\/1"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,19]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Human cytomegalovirus (HCMV) is a threat to immunologically weak patients. HCMV cannot yet be eliminated with a vaccine, despite recent advances.<\/jats:p><\/jats:sec><jats:sec><jats:title>Sources of data<\/jats:title><jats:p>Sources of data are recently published research papers and reviews about HCMV treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas of agreement<\/jats:title><jats:p>Current antivirals target the UL54 DNA polymerase and are limited by nephrotoxicity and viral resistance. Promisingly, letermovir targets the HCMV terminase complex and has been recently approved by the FDA and EMA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas of controversy<\/jats:title><jats:p>Should we screen newborns for HCMV, and use antivirals to treat sensorineural hearing loss after congenital HCMV infection?<\/jats:p><\/jats:sec><jats:sec><jats:title>Growing points<\/jats:title><jats:p>Growing points are developing drugs against latently infected cells. In addition to small molecule inhibitors, a chemokine-based fusion toxin protein, F49A-FTP, has shown promise in killing both lytically and latently infected cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Areas timely for developing research<\/jats:title><jats:p>We need to understand what immune responses are required to control HCMV, and how best to raise these immune responses with a vaccine.<\/jats:p><\/jats:sec>","DOI":"10.1093\/bmb\/ldz031","type":"journal-article","created":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T03:17:30Z","timestamp":1565925450000},"page":"5-17","source":"Crossref","is-referenced-by-count":71,"title":["Advances in the treatment of cytomegalovirus"],"prefix":"10.1093","volume":"131","author":[{"given":"B A","family":"Krishna","sequence":"first","affiliation":[{"name":"Department of Medicine, Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge, UK"},{"name":"Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Wills","sequence":"additional","affiliation":[{"name":"Department of Medicine, Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J H","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Department of Medicine, Addenbrooke\u2019s Hospital, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,3]]},"reference":[{"key":"2019103102393833600_ref1","doi-asserted-by":"crossref","first-page":"19755","DOI":"10.1073\/pnas.1115861108","article-title":"High-resolution human cytomegalovirus transcriptome","volume":"108","author":"Gatherer","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019103102393833600_ref2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1126\/science.1227919","article-title":"Decoding human cytomegalovirus","volume":"338","author":"Stern-Ginossar","year":"2012","journal-title":"Science"},{"key":"2019103102393833600_ref3","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1099\/vir.0.81891-0","article-title":"Latency and reactivation of human cytomegalovirus","volume":"87","author":"Sinclair","year":"2006","journal-title":"J Gen Virol"},{"key":"2019103102393833600_ref4","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1053\/jinf.2001.0949","article-title":"Clinical aspects and management of cytomegalovirus infection","volume":"44","author":"Sissons","year":"2002","journal-title":"J Infect"},{"key":"2019103102393833600_ref5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1743-422X-5-47","article-title":"Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review","volume":"5","author":"Rafailidis","year":"2008","journal-title":"Virol J"},{"key":"2019103102393833600_ref6","first-page":"e02245","article-title":"Severe symptomatic primary HCMV infection despite effective innate and adaptive immune responses","author":"Riou","year":"2016","journal-title":"J Virol"},{"key":"2019103102393833600_ref7","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/infdis\/jiu837","article-title":"Alveolar macrophages isolated directly from human cytomegalovirus (HCMV)--seropositive individuals are sites of HCMV reactivation in vivo","volume":"211","author":"Poole","year":"2015","journal-title":"J Infect Dis"},{"key":"2019103102393833600_ref8","doi-asserted-by":"crossref","first-page":"e16103","DOI":"10.1371\/journal.pone.0016103","article-title":"Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States","volume":"6","author":"Simanek","year":"2011","journal-title":"PLoS One"},{"key":"2019103102393833600_ref9","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/jnnp-2014-307727","article-title":"Cytomegalovirus and glioma: putting the cart before the horse","volume":"86","author":"Dey","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2019103102393833600_ref10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/neuonc\/nor227","article-title":"Consensus on the role of human cytomegalovirus in glioblastoma","volume":"14","author":"Dziurzynski","year":"2012","journal-title":"Neuro Oncol"},{"key":"2019103102393833600_ref11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/cid\/cir074","article-title":"Guillain--Barr\u00e9 syndrome following primary cytomegalovirus infection: a prospective cohort study","volume":"52","author":"Orlikowski","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019103102393833600_ref12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/acel.12059","article-title":"Cytomegalovirus infection is associated with increased mortality in the older population","volume":"12","author":"Savva","year":"2013","journal-title":"Aging Cell"},{"key":"2019103102393833600_ref13","first-page":"63","article-title":"Cytomegalovirus cell tropism","volume":"325","author":"Sinzger","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"2019103102393833600_ref14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3390\/v10080405","article-title":"Maternal immunity and the natural history of congenital human cytomegalovirus infection","volume":"10","author":"Britt","year":"2018","journal-title":"Viruses"},{"key":"2019103102393833600_ref15","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2018-316010","article-title":"Economic cost of congenital CMV in the UK","author":"Retzler","year":"2018","journal-title":"Arch Dis Child"},{"key":"2019103102393833600_ref16","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJM200105033441804","article-title":"Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity","volume":"344","author":"Boppana","year":"2001","journal-title":"N Engl J Med"},{"key":"2019103102393833600_ref17","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1136\/archdischild-2012-301885.79","article-title":"Targeted salivary screening for congenital CMV in the UK is feasible, acceptable and may improve hearing outcomes","volume":"97","author":"Williams","year":"2012","journal-title":"Arch Dis Child"},{"key":"2019103102393833600_ref18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00023-08","article-title":"Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention","volume":"22","author":"Cheeran","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2019103102393833600_ref19","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/S1473-3099(17)30143-3","article-title":"Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy","volume":"17","author":"Rawlinson","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2019103102393833600_ref20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/archdischild-2015-309656","article-title":"Fifteen-minute consultation: diagnosis and management of congenital CMV","volume":"101","author":"Shah","year":"2016","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"2019103102393833600_ref21","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"2019103102393833600_ref22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrneph.2010.141","article-title":"Management of cytomegalovirus infection in solid organ transplantation","volume":"6","author":"Kotton","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"2019103102393833600_ref23","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"Cytomegalovirus in solid organ transplant recipients","volume":"9","author":"Humar","year":"2009","journal-title":"Am J Transplant"},{"key":"2019103102393833600_ref24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/CMR.13.1.83","article-title":"New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients","volume":"13","author":"Sia","year":"2000","journal-title":"Clin Microbiol Rev"},{"key":"2019103102393833600_ref25","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/01.qco.0000136933.67920.dd","article-title":"Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients","volume":"17","author":"Pereyra","year":"2004","journal-title":"Curr Opin Infect Dis"},{"key":"2019103102393833600_ref26","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1399-3062.2010.00504.x","article-title":"Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy","volume":"12","author":"George","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"2019103102393833600_ref27","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/j.bbmt.2015.07.019","article-title":"Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation: the Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group","volume":"21","author":"Takenaka","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019103102393833600_ref28","first-page":"417","article-title":"Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease","volume":"325","author":"Britt","year":"2008","journal-title":"Curr Top Microbiol Immunol"},{"key":"2019103102393833600_ref29","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.bbmt.2007.08.049","article-title":"Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease","volume":"13","author":"van Burik","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019103102393833600_ref30","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.bbmt.2008.09.001","article-title":"The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia","volume":"14","author":"Delgado","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019103102393833600_ref31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"2019103102393833600_ref32","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/cid\/ciq055","article-title":"Adoptive therapy of cytomegalovirus-specific T lymphocytes: is less more?","volume":"52","author":"Perales","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2019103102393833600_ref33","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-018-0209-2","article-title":"Adoptive transfer of cellular immunity against cytomegalovirus by virus-specific lymphocytes from a third-party family donor","volume":"53","author":"Lindemann","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"2019103102393833600_ref34","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.coph.2008.07.002","article-title":"Antiviral strategies to combat cytomegalovirus infections in transplant recipients","volume":"8","author":"Lischka","year":"2008","journal-title":"Curr Opin Pharmacol"},{"key":"2019103102393833600_ref35","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)---seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J Infect Dis"},{"key":"2019103102393833600_ref36","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2007.03.009","article-title":"Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis","volume":"13","author":"Battiwalla","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019103102393833600_ref37","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"2019103102393833600_ref38","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/ajt.13044","article-title":"Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis","volume":"15","author":"Mumtaz","year":"2015","journal-title":"Am J Transplant"},{"key":"2019103102393833600_ref39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/jpids\/pit048","article-title":"Ganciclovir, foscarnet, and cidofovir: antiviral drugs not just for cytomegalovirus","volume":"2","author":"Upadhyayula","year":"2013","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2019103102393833600_ref40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: a close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol Rev"},{"key":"2019103102393833600_ref41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019103102393833600_ref42","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2165\/10898540-000000000-00000","article-title":"New developments in the management of cytomegalovirus infection after solid organ transplantation","volume":"70","author":"Eid","year":"2010","journal-title":"Drugs"},{"key":"2019103102393833600_ref43","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1111\/tid.12156","article-title":"Leflunomide as part of the treatment for multidrug-resistant cytomegalovirus disease after lung transplantation: case report and review of the literature","volume":"15","author":"Verkaik","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"2019103102393833600_ref44","author":"NICE","year":"2018"},{"key":"2019103102393833600_ref45","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2019103102393833600_ref46","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1128\/JVI.01952-10","article-title":"Human cytomegalovirus UL97 kinase and nonkinase functions mediate viral cytoplasmic secondary envelopment","volume":"85","author":"Goldberg","year":"2011","journal-title":"J Virol"},{"key":"2019103102393833600_ref47","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2019103102393833600_ref48","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2018.03.006","article-title":"Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections","author":"Frange","year":"2018","journal-title":"Med Mal Infect"},{"key":"2019103102393833600_ref49","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1093\/ofid\/ofw172.1834","article-title":"Maribavir versus valganciclovir for preemptive treatment of cytomegalovirus (CMV) viremia: a randomized, dose-ranging, phase 2 study among hematopoietic stem cell transplant (SCT) and solid organ transplant (SOT) recipients","volume":"3","author":"Maertens","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2019103102393833600_ref50","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"2019103102393833600_ref51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.coviro.2011.10.011","article-title":"Maribavir and human cytomegalovirus\u2014what happened in the clinical trials and why might the drug have failed?","volume":"1","author":"Marty","year":"2011","journal-title":"Curr Opin Virol"},{"key":"2019103102393833600_ref52","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1097\/TP.0000000000001097","article-title":"CMV immunoglobulins for the treatment of CMV infections in thoracic transplant recipients","volume":"100","author":"Schulz","year":"2016","journal-title":"Transplantation"},{"key":"2019103102393833600_ref53","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N Engl J Med"},{"key":"2019103102393833600_ref54","doi-asserted-by":"crossref","first-page":"8427","DOI":"10.1073\/pnas.1509392112","article-title":"Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivo","volume":"112","author":"Spiess","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019103102393833600_ref55","doi-asserted-by":"crossref","first-page":"E10586","DOI":"10.1073\/pnas.1710522114","article-title":"Transcriptome-wide characterization of human cytomegalovirus in natural infection and experimental latency","volume":"114","author":"Cheng","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019103102393833600_ref56","article-title":"Cytomegalovirus latency and reactivation: recent insights into an age old problem","author":"Dupont","year":"2015","journal-title":"Rev Med Virol"},{"key":"2019103102393833600_ref57","doi-asserted-by":"crossref","first-page":"e00013","DOI":"10.1128\/mBio.00013-18","article-title":"Defining the transcriptional landscape during cytomegalovirus latency with single-cell RNA sequencing","volume":"9","author":"Shnayder","year":"2018","journal-title":"MBio"},{"key":"2019103102393833600_ref58","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.idc.2010.01.008","article-title":"Cytomegalovirus in hematopoietic stem cell transplant recipients","volume":"24","author":"Ljungman","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"2019103102393833600_ref59","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1126\/science.1235047","article-title":"Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection","volume":"340","author":"Weekes","year":"2013","journal-title":"Science (New York, NY)"},{"key":"2019103102393833600_ref60","article-title":"HCMV US28 is important for latent infection of hemtopoietic progenitor cells","volume":"02507","author":"Humby","year":"2015","journal-title":"J Virol"},{"key":"2019103102393833600_ref61","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1038\/ncomms14321","article-title":"Targeting the latent cytomegalovirus reservoir with an antiviral fusion toxin protein","volume":"8","author":"Krishna","year":"2017","journal-title":"Nat Commun"},{"key":"2019103102393833600_ref62","article-title":"The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?","author":"Wills","year":"2014","journal-title":"Cell Mol Immunol"},{"key":"2019103102393833600_ref63","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1073\/pnas.0408994102","article-title":"Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers","volume":"102","author":"Reeves","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019103102393833600_ref64","doi-asserted-by":"crossref","DOI":"10.1038\/srep24674","article-title":"Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells","volume":"6","author":"Krishna","year":"2016","journal-title":"Sci Rep"},{"key":"2019103102393833600_ref65","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01754-17","article-title":"Latency-associated expression of human cytomegalovirus US28 attenuates cell signaling pathways to maintain latent infection","volume":"8","author":"Krishna","year":"2017","journal-title":"MBio"},{"key":"2019103102393833600_ref66","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1086\/421999","article-title":"Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee","volume":"39","author":"Arvin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019103102393833600_ref67","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1086\/652438","article-title":"Cytomegalovirus seroprevalence in the United States: the National Health and nutrition examination surveys, 1988\u20132004","volume":"50","author":"Bate","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2019103102393833600_ref68","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1016\/j.vaccine.2012.09.056","article-title":"The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB","volume":"30","author":"Lilja","year":"2012","journal-title":"Vaccine"},{"key":"2019103102393833600_ref69","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/infdis\/jiw365","article-title":"A phase 1 study of 4 live, recombinant human cytomegalovirus Towne\/Toledo chimera vaccines in cytomegalovirus\u2013seronegative men","volume":"214","author":"Adler","year":"2016","journal-title":"J Infect Dis"},{"key":"2019103102393833600_ref70","first-page":"88","article-title":"Prevention of cytomegalovirus disease in renal allograft recipients","volume":"80","author":"Balfour","year":"1991","journal-title":"Scand J Infect Dis Suppl"},{"key":"2019103102393833600_ref71","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-114-7-525","article-title":"Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial","volume":"114","author":"Plotkin","year":"1991","journal-title":"Ann Intern Med"},{"key":"2019103102393833600_ref72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/infdis\/171.1.26","article-title":"Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age","volume":"171","author":"Adler","year":"1995","journal-title":"J Infect Dis"},{"key":"2019103102393833600_ref73","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/infdis\/159.5.860","article-title":"Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge","volume":"159","author":"Plotkin","year":"1989","journal-title":"J Infect Dis"},{"key":"2019103102393833600_ref74","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-016-0653-5","article-title":"Cytomegalovirus vaccines: current status and future prospects","volume":"76","author":"Anderholm","year":"2016","journal-title":"Drugs"},{"key":"2019103102393833600_ref75","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.3389\/fimmu.2018.02214","article-title":"HCMV-encoded NK modulators: lessons from in vitro and in vivo genetic variation","volume":"9","author":"Patel","year":"2018","journal-title":"Front Immunol"},{"key":"2019103102393833600_ref76","doi-asserted-by":"crossref","first-page":"e02033","DOI":"10.1128\/JVI.02033-16","article-title":"Neutralization of diverse human cytomegalovirus strains conferred by antibodies targeting viral gH\/gL\/pUL128-131 pentameric complex","volume":"91","author":"Ha","year":"2017","journal-title":"J Virol"},{"key":"2019103102393833600_ref77","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s11262-017-1452-0","article-title":"Genomic analysis of chimeric human cytomegalovirus vaccine candidates derived from strains Towne and Toledo","volume":"53","author":"Su\u00e1rez","year":"2017","journal-title":"Virus Genes"},{"key":"2019103102393833600_ref78","doi-asserted-by":"crossref","first-page":"11107","DOI":"10.1128\/JVI.01554-13","article-title":"Cytomegalovirus vaccine strain towne-derived dense bodies induce broad cellular immune responses and neutralizing antibodies that prevent infection of fibroblasts and epithelial cells","volume":"87","author":"Cayatte","year":"2013","journal-title":"J Virol"},{"key":"2019103102393833600_ref79","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"2019103102393833600_ref80","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1093\/infdis\/jir138","article-title":"Glycoprotein B vaccine is capable of boosting both antibody and CD4 T-cell responses to cytomegalovirus in chronically infected women","volume":"203","author":"Sabbaj","year":"2011","journal-title":"J Infect Dis"},{"key":"2019103102393833600_ref81","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/S0264-410X(00)00377-7","article-title":"Encouraging prospects for immunisation against primary cytomegalovirus infection","volume":"19","author":"Griffiths","year":"2001","journal-title":"Vaccine"},{"key":"2019103102393833600_ref82","doi-asserted-by":"crossref","first-page":"e00268","DOI":"10.1128\/CVI.00268-17","article-title":"Progress toward development of a vaccine against congenital cytomegalovirus infection","volume":"24","author":"Schleiss","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"2019103102393833600_ref83","article-title":"Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies","volume":"201800224","author":"Baraniak","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"2019103102393833600_ref84","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1126\/science.1185350","article-title":"Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus","volume":"328","author":"Hansen","year":"2010","journal-title":"Science"},{"key":"2019103102393833600_ref85","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2055-6640(20)30872-4","article-title":"Cytomegalovirus vaccines under clinical development","volume":"2","author":"Schleiss","year":"2016","journal-title":"J Virus Erad"},{"key":"2019103102393833600_ref86","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJMoa043337","article-title":"Passive immunization during pregnancy for congenital cytomegalovirus infection","volume":"353","author":"Nigro","year":"2005","journal-title":"N Engl J Med"},{"key":"2019103102393833600_ref87","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2353\/ajpath.2006.050482","article-title":"Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal fc receptor-mediated transcytosis","volume":"168","author":"Maidji","year":"2006","journal-title":"Am J Pathol"},{"key":"2019103102393833600_ref88","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1056\/NEJMoa064040","article-title":"Loss of vaccine-induced immunity to varicella over time","volume":"356","author":"Chaves","year":"2007","journal-title":"N Engl J Med"},{"key":"2019103102393833600_ref89","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.06054","article-title":"Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease","volume":"4","author":"Petro","year":"2015","journal-title":"Elife"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/131\/1\/5\/30329677\/ldz031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/131\/1\/5\/30329677\/ldz031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,16]],"date-time":"2021-01-16T21:09:58Z","timestamp":1610831398000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bmb\/article\/131\/1\/5\/5580529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,10,3]]},"published-print":{"date-parts":[[2019,9,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bmb\/ldz031","relation":{},"ISSN":["0007-1420","1471-8391"],"issn-type":[{"value":"0007-1420","type":"print"},{"value":"1471-8391","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,9]]}}}